ST香雪 (300147)

Xiangxue Pharmaceutical Co., Ltd.

ASZ

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 66127.90
  • Circulating A-Shares(W): 65739.84
  • Earnings Per Share(RMB): -0.5500
  • Net Assets Per Share(RMB): 1.0474
  • Operating Revenue(W RMB): 114591.32
  • Total Profit(W RMB): -33522.17
  • Net Profit Attributable to Parent(W RMB): -36190.20
  • Net Profit Growth Rate(%): -66.16
  • Weighted Return on Equity(%): -41.0000
  • Operating Cash Flow Per Share(RMB): 0.0410
  • Undistributed Profit Per Share(RMB): -3.3241
  • Capital Reserve Per Share(RMB): 3.2547

2. Main Business

The main business covers:

  • Traditional Chinese Medicine Manufacturing

3. Company Basic Information

  • Company Name: Xiangxue Pharmaceutical Co., Ltd.
  • Listing Date: 2010-12-15
  • Industry: Pharmaceutical Manufacturing
  • Address: No.2 Jinfengyuan Road, Science City, Guangzhou Economic & Technological Development District, Luogang District, Guangzhou City, Guangdong Province
  • Website: www.xphcn.com
  • Company Profile: The company was established through the overall restructuring of Guangzhou Luogang Pharmaceutical Factory. On December 16, 1997, based on the approval from the Guangzhou Economic Restructuring Committee, five promoters including Kunlun Investment jointly signed the "Promoter Agreement" to establish Guangzhou Xiangxue Pharmaceutical Co., Ltd. Using the net assets of Luogang Pharmaceutical Factory as of November 30, 1997, assessed at RMB 49,004,291.23, the company was established by converting these assets into 45 million shares. The company obtained its business license on December 29, 1997.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Guangzhou Kunlun Investment Co., Ltd. General Legal Person 14940.99 22.73
2 Guangzhou Luogang Water Supply Co., Ltd. General Legal Person 2683.23 4.08
3 Guangdong Wanming Construction Engineering Co., Ltd. General Legal Person 358.59 0.55

5. Concept Sectors

  • ST Sector
  • Immunotherapy
  • Mask Protection
  • Assisted Reproduction
  • Innovative Drugs

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information